Radiotherapy for Pediatric Tumors

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Childhood, Adolescent and Young Adult Oncology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 1269

Special Issue Editors


E-Mail Website
Guest Editor
Department of Radiation Oncology, Brigham and Women’s Hospital, Dana‐Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Interests: neuroblastoma; pediatric brain tumors; pediatric cancers; pediatric sarcomas; stereotactic body radiation therapy; stereotactic radiosurgery; translational clinical trials

E-Mail Website
Guest Editor
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
Interests: brain and spine tumors; gastrointestinal tumors; sarcomas; pediatrics; proton therapy; radiosurgery

Special Issue Information

Dear Colleagues,

Radiotherapy plays an important role in the treatment of many pediatric tumors. Radiation treatment can improve local control and is critical in curing certain types of pediatric malignancies. Furthermore, radiotherapy can help palliative symptoms after tumor recurrence and address oligometastatic or oligoprogressive disease. However, radiation can lead to acute and long-term toxicity, some of which can be morbid, especially for pediatric patients. In recent decades, advances in radiation technology and planning have contributed to improvements in outcomes, including the reduction in toxicity. Future research is underway to investigate new strategies to improve local control and survival in pediatric tumors with poor prognosis and decrease acute and long-term toxicity after radiation.

This Special Issue brings together leading experts and researchers to discuss various aspects of radiotherapy for pediatric tumors. This Special Issue will seek to explore interesting and challenging questions from a wide range of topics, including, but not limited to, the following: clinical outcomes after radiotherapy, including toxicity; the development of novel radiotherapy treatment paradigms; preclinical research to identify new radiosensitizers; and long-term survivorship care after radiation treatment within the context of pediatric tumors. Together, this Special Issue will serve as a valuable resource for clinicians, researchers, and healthcare professionals involved in the care of pediatric patients with tumors, and it will aim to foster the development of novel treatment strategies and improve the quality of life for these young patients. In this Special Issue, original research articles and reviews are welcome.

Dr. Kevin X. Liu
Dr. Nicholas DeNunzio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric tumors
  • radiotherapy
  • proton radiotherapy
  • photon radiotherapy
  • brachytherapy
  • stereotactic body radiotherapy
  • stereotactic radiosurgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 3956 KiB  
Communication
Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis
by Célia Gotorbe, Fabien Segui, William Echavidre, Jérôme Durivault, Thays Blanchard, Valérie Vial, Marina Pagnuzzi-Boncompagni, Rémy Villeneuve, Régis Amblard, Nicolas Garnier, Cécile Ortholan, Benjamin Serrano, Vincent Picco, Jacques Pouysségur, Milica Vucetic and Christopher Montemagno
Curr. Oncol. 2024, 31(11), 7390-7402; https://doi.org/10.3390/curroncol31110545 - 20 Nov 2024
Viewed by 749
Abstract
Medulloblastoma, a malignant pediatric brain tumor, has a poor prognosis upon relapse, highlighting a critical clinical need. Our previous research linked medulloblastoma cell radioresistance to integrin-αvβ3 expression. β3-depleted (β3_KO) medulloblastoma cells exhibit lipid hydroxyperoxide accumulation after radiotherapy, indicating ferroptosis, a regulated cell death [...] Read more.
Medulloblastoma, a malignant pediatric brain tumor, has a poor prognosis upon relapse, highlighting a critical clinical need. Our previous research linked medulloblastoma cell radioresistance to integrin-αvβ3 expression. β3-depleted (β3_KO) medulloblastoma cells exhibit lipid hydroxyperoxide accumulation after radiotherapy, indicating ferroptosis, a regulated cell death induced by ROS and inhibited by antioxidants such as cysteine, glutathione (GSH), and glutathione peroxidase 4 (GPx4). However, the link between αvβ3 expression, ferroptosis inhibition, and sensitivity to radiotherapy remains unclear. We showed that irradiated β3_KO medulloblastoma cells primarily die by ferroptosis, with β3-subunit expression correlating with radiotherapy sensitivity and anti-ferroptotic protein levels. Our findings suggest that integrin-αvβ3 signaling boosts oxidative stress resilience via mTORC1. Thus, targeting integrin-αvβ3 could enhance radiotherapy efficacy in medulloblastoma by inducing ferroptotic cell death. Full article
(This article belongs to the Special Issue Radiotherapy for Pediatric Tumors)
Show Figures

Figure 1

Back to TopTop